Humira Market Size, Share & Trends Analysis Report By Product (Branded, Biosimilar), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Humira Market Size & Trends

The global Humira market size was estimated at USD 10.34 billion in 2024 and is projected to decline at a CAGR of -11.29% from 2025 to 2030. The market decline is primarily attributed to the increasing availability of biosimilars following patent expirations. Despite a continued prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease, the competitive landscape intensifies with the entry of cost-effective alternatives. Although pharmaceutical companies continue investing in R&D and pursuing geographic expansion and collaborations, pricing pressures and shifts in patient preference toward newer therapies are expected to further impact Humira’s market share.

The expansion of biosimilars is reshaping the Humira market by increasing accessibility and affordability. In 2024, the U.S. Food and Drug Administration (FDA) approved numerous biosimilars, such as Amjevita, Hyrimoz, and Yuflyma, which have introduced significant pricing competition, reducing treatment costs and expanding patient access. Healthcare providers and insurers are increasingly adopting biosimilars, driving broader use of adalimumab in autoimmune disease management. In response, AbbVie has introduced innovations, such as citrate-free formulations, to maintain product differentiation. The growing presence of biosimilars enhances overall adalimumab utilization, supporting market volume despite price erosion. However, the market's growth is declining, even as the increasing disease prevalence supports sustained demand for biologic therapies like Humira.

The rising global prevalence of autoimmune diseases remains a structural driver for the Humira market. A 2023 study published by The Lancet, involving 22 million individuals, estimated that autoimmune diseases affect approximately one in ten people worldwide. Genetic predisposition, environmental triggers, and improved healthcare access drive this growth. Higher prevalence rates are reported in Northern Europe and North America, where advanced diagnostics and disease awareness are well established. In emerging markets across Asia, Africa, and Australia, industrialization and lifestyle changes contribute to a sharp increase in incidence rates. The expanding global autoimmune patient pool supports sustained demand for biologic therapies such as Humira.

The rising burden of Crohn’s disease further contributes to Humira demand. Data from Minnesota indicates that 19% of Crohn’s patients present with complications within 90 days of diagnosis, and 50% develop intestinal complications over 20 years. Crohn’s disease typically affects the ileum, the ileocolonic region, or the colon, with limited migration over time. Humira remains a long-term treatment option across all disease locations. Incidence is highest among Northern Europeans and individuals of Jewish descent, but emerging markets in Asia, Africa, and Australasia are witnessing increasing rates due to industrialization. The chronic and progressive nature of Crohn’s disease supports ongoing therapeutic demand.

While Humira faces a declining revenue trajectory due to biosimilar competition and loss of exclusivity, these underlying drivers continue to stabilize market volumes. The global expansion of autoimmune diseases, broader biosimilar adoption, and the increasing burden of Crohn’s disease maintain demand for adalimumab therapies. Additionally, biosimilars are unlocking previously untapped markets by making biologic treatment accessible at lower costs. As a result, although the market value is contracting, the overall volume of adalimumab utilization remains supported by fundamental growth factors.

Pipeline Analysis

The following analysis outlines key developments in the pipeline for autoimmune and inflammatory conditions, focusing on drugs targeting diseases such as rheumatoid arthritis, ulcerative colitis, and plaque psoriasis. Notable highlights include several promising treatments advancing through Phase 3 trials, including adalimumab for plaque psoriasis and ulcerative colitis, with launches expected between 2027 and 2030. Upadacitinib, aimed at rheumatoid arthritis, and Ixekizumab, for juvenile psoriatic arthritis, also show strong potential, with anticipated launches during the forecast period. The progress across various phases underscores the ongoing innovation in the autoimmune therapeutics market, with several therapies poised to address unmet clinical needs.

Biosimilar Market Growth

The introduction of Humira biosimilars is poised to disrupt the autoimmune and inflammatory disease treatment market significantly. Following Humira’s patent expiration, biosimilars like Amgen’s Amjevita, Samsung Bioepis’ Renflexis, and Celltrion’s Remsima are offering 20-30% lower costs, making them an attractive alternative for healthcare providers and payers seeking cost containment. This shift reduces healthcare expenditures and increases patient access to essential biologics, particularly in cost-sensitive regions. Biosimilars are expected to drive a more competitive market, forcing pricing pressure on biologic therapies and opening up opportunities in emerging markets.

As biosimilars continue to enter the market, they present significant revenue opportunities for pharmaceutical companies. The growing demand for cost-effective biologic treatments across therapeutic areas like rheumatology, gastroenterology, and oncology drives the market's expansion. The transition to biosimilars is especially impactful in regions with high healthcare costs and limited access to biologic therapies, making biosimilars a critical solution to improving patient access and reducing healthcare burdens.

Furthermore, the competition introduced by biosimilars is leading to innovation in pricing strategies and the development of new biologic therapies. Companies are encouraged to invest in advanced manufacturing technologies to enhance production efficiency and meet the growing demand for biologics. With the increased focus on value-based care, biosimilars offer a sustainable path forward by maintaining clinical efficacy while delivering cost savings, making them a compelling option for healthcare systems globally.

Market Concentration & Characteristics

The Humira market is advancing with innovations driven by the expanding biosimilar landscape. The approval of SIMLANDI (adalimumab-ryvk) introduces a significant leap forward, as it becomes the first high-concentration, citrate-free biosimilar to Humira with FDA-approved interchangeable status. This innovation facilitates pharmacy-level substitution, eliminating the need for prescriber approval, akin to generic drugs. Additionally, SIMLANDI’s citrate-free formulation reduces common injection site reactions, improving patient experience and adherence. These advancements contribute to increased affordability and access, positioning biosimilars as a transformative force in the biologics market.

The Humira market sets a high participation threshold due to complex biologic drug development requirements, rigorous regulatory pathways, and AbbVie's historically strong patent portfolio. Biosimilar development involves heavy R&D expenditures, advanced manufacturing capabilities, and extensive clinical testing to demonstrate similarity in safety and efficacy. Additionally, the production of monoclonal antibodies like Humira demands elaborate operations that come with high expenses and limited replicability. AbbVie's established global market presence, brand recognition, and long-standing relationships with healthcare providers and payers further solidify its market leadership, making it challenging for new entrants to gain significant market share quickly.

Rigorous compliance standards significantly impact the Humira market. These bodies mandate comprehensive clinical trials and rigorous pharmacovigilance to ensure long-term safety and efficacy, especially given Humira’s wide range of autoimmune indications. Pricing and reimbursement policies significantly influence market access, as high treatment costs necessitate favorable insurance coverage. Regulatory harmonization across regions is essential for global adoption, particularly in emerging markets.

Humira competes with a variety of other biologic treatments and small-molecule medications, specifically in the management of autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Amjevita, Hadlima, and Hyrimoz biosimilars provide affordable options, and Enbrel (etanercept), Remicade (infliximab), and Stelara (ustekinumab) biologics are also therapeutic alternatives. In the face of this competition, however, Humira's established effectiveness, wide range of therapeutic use, and unwavering trust among physicians sustain its usage. Patient familiarity, ease of administration, and ample clinical support additionally secure its stronghold in the marketplace.

AbbVie has expanded its Humira portfolio into high-growth markets such as Asia-Pacific, Latin America, and Europe, driven by rising autoimmune disease prevalence and improving healthcare infrastructure. For instance, Humira is also approved in Japan for treating intestinal Behçet’s disease, generalized pustular psoriasis, and pyoderma gangrenosum. The company focuses on securing regulatory approvals, optimizing pricing strategies, and strengthening reimbursement frameworks to enhance patient access. Strategic partnerships with healthcare providers and government initiatives support market penetration, while investments in local manufacturing and distribution networks address supply chain challenges.

Product Insights

The branded Humira segment dominated the Humira market, accounting for 87.0 % of the share in 2024, driven by its strong brand recognition, proven efficacy, and long-standing presence. Since its initial approval, Humira has built a robust reputation across multiple therapeutic areas, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis. Its broad range of indications and extensive clinical trial data have contributed to deep market penetration and widespread physician and patient trust. AbbVie has reinforced its market dominance through strategic life-cycle management tactics, including introducing new formulations such as citrate-free versions and enhanced auto-injectors for improved patient comfort. For instance, according to AbbVie’s Full-Year 2024 financial report, Humira remains a significant contributor to the company’s immunology portfolio. In 2024, global Humira net revenues totaled USD 8.993 billion, while the total global net revenues from AbbVie’s immunology portfolio reached USD 26.682 billion. This indicates Humira has accounted for approximately 33.7% of AbbVie’s total immunology revenue for the year.

Biosimilar products are projected to grow at the fastest rate in the Humira market, driven by cost-effectiveness, regulatory approvals, and increasing acceptance among healthcare providers and patients. With the expiration of Humira’s patents in major markets, biosimilars such as Amjevita (Amgen) and Hyrimoz (Sandoz) have gained traction. For example, in April 2024, Evernorth Health Services announced an initiative to provide a Humira biosimilar at zero out-of-pocket cost for eligible patients through its specialty pharmacy, Accredo. Supported by Quallent Pharmaceuticals, Evernorth’s private-label distributor, the program is enabled through partnerships with multiple manufacturers offering both high- and low-concentration interchangeable biosimilars.

Application Insights

Rheumatoid arthritis (RA) accounted for 20.5% of the Humira market share in 2024. The study "Global, regional, and national burden of rheumatoid arthritis, 1990-2020," published in The Lancet Rheumatology, estimates global RA prevalence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2020, with forecasts through 2050. In 2020, 17.6 million people had RA, marking a 14.1% increase in age-standardized global prevalence since 1990. While RA mortality declined by 23.8%, DALYs, primarily driven by years lived with disability, increased. RA cases are projected to reach 31.7 million by 2050, highlighting the growing need for early diagnosis and treatment access.

The Ulcerative Colitis (UC) disease segment is projected to experience moderate growth in the Humira market, driven by the rising prevalence of inflammatory bowel diseases (IBD), particularly in North America and Northern Europe. These regions report the highest global incidence and prevalence rates of IBD, highlighting the growing need for effective biologic therapies. UC affects approximately 156 to 291 individuals per 100,000, with an annual incidence ranging from 9 to 20 cases per 100,000 persons. It exhibits a bimodal age distribution, with peak onset between 15-30 years and a smaller secondary peak between 50-70 years, emphasizing the long-term therapeutic needs of a diverse patient population. While UC shows no strong gender preference, it is more commonly observed in non-smokers and those who have recently quit smoking.

Distribution Channel Insights

Hospital pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the increasing prevalence of diseases that require specialist oversight typically available in hospital settings. Hospitals provide comprehensive care, ensuring patients receive timely and coordinated treatment, which is crucial for biologic therapies like Humira. Hospitals maintain strong, well-coordinated supply chain networks through long-standing partnerships with pharmaceutical manufacturers and distributors. These integrated systems help ensure a reliable and uninterrupted supply of Humira, enabling consistent access for patients who rely on the medication for chronic autoimmune conditions. This streamlined logistics framework reduces the risk of stock shortages and delays in treatment delivery. Their infrastructure and trained staff support the proper storage, temperature control, and handling protocols required for drugs like Humira, ensuring adherence to safety and quality regulations throughout the supply process.

Online pharmacies are experiencing the significant growth in the Humira market due to increasing consumer preference for digital healthcare solutions, driven by technological advancements and changing consumer preferences. Enhanced telemedicine services and direct-to-consumer sales models have further accelerated adoption. Regulatory approvals for online prescription fulfillment and expanding insurance coverage contribute to market penetration. While retail pharmacies remain dominant, online platforms benefit from accessibility, competitive pricing, and discreet purchasing options, positioning them as the fastest-growing distribution channel for Humira-based therapies.

Regional Insights

The North America Humira market holds a leading position in 2024, accounting for 85.7% of the global share. The region benefits from favorable reimbursement policies, increasing weight management awareness, and rising prescriptions for off-label use. The U.S. dominates due to robust pharmaceutical regulations, active patient engagement, and significant investments in autoimmune therapeutics. Additionally, market growth is fueled by ongoing clinical advancements, including oral Humira formulations. With continuous regulatory oversight and expanding treatment accessibility, North America remains the largest market for Humira-based therapies.

U.S. Humira Market Trends

The U.S. dominates the Humira market in North America. This is due to a high autoimmune prevalence and strong healthcare infrastructure. For instance, according to the Report of the Office of Autoimmune Disease Research by NIH, Autoimmune diseases are estimated to affect 7% to 8% of the United States population, with more than 23.5 million Americans living with autoimmune diseases. Early regulatory approvals and extensive R&D activities contribute to market expansion. The rising adoption of Humira for chronic diseases is reshaping prescribing trends.

Europe Humira Market Trends

Europe exhibits steady Humira market growth, led by Germany, France, and the UK. The region benefits from increased biosimilar adoption post-patent expiry, updated EMA guidelines on immunomodulators, and emphasis on pharmacoeconomics. National health services promote switching programs to reduce costs, while local manufacturers are boosting biosimilar production capacity.

The UK Humira market is expanding due to NHS-backed biosimilar rollout programs and personalized treatment pathways for chronic inflammatory diseases. For instance, in January 2024, the UK government introduced the 2024 Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), a USD 500 million joint initiative with the pharmaceutical industry. It supports clinical trials, health technology assessment, and manufacturing, aiming to boost access to biosimilars and personalized treatments. Government funding for biopharmaceutical R&D and accelerated approval pathways for biosimilars are enhancing market competitiveness. The role of community pharmacies in biosimilar dispensing is also increasing.

The Germany Humira market leads the Europe market due to its advanced biopharmaceutical manufacturing and robust healthcare system. Hospital formularies have been optimized to include cost-effective biosimilar versions, supported by government incentives and electronic prescription systems that streamline biologic therapies.

The France Humira market is witnessing rapid expansion, driven by rising prevalence of inflammatory bowel disease. According to NIH 2024 epidemiology data, in France, a total number of 22,879 new cases of inflammatory bowel disease (IBD) were recorded over the study period, with 59% being Crohn’s disease, 38% ulcerative colitis, and 3% unclassified IBD. The overall incidence rates were 12.7 per 100,000 people per year for IBD, 7.2 for CD, and 5.1 for UC. Notably, the incidence of Crohn’s disease rose from 5.1 in 1988-1990 to 7.9 in 2015-2017, showing an average annual growth rate of 1.9%. Ulcerative colitis cases increased from 4.5 to 6.1, with a 1.3% annual growth rate. This trend in disease incidence underscores the growing demand for effective biologic therapies like Humira, positioning France as a key market for continued investment and therapeutic innovation.

Asia Pacific Humira Market Trends

The Asia-Pacific Humira market is rapidly expanding, driven by increasing access to biologics, government funding for chronic disease treatment, and growing partnerships with multinational biopharma companies. For instance, in October 2024, representatives from various Asia-Pacific nations formally adopted strategic frameworks focused on health financing and digital health, as part of a collective push toward achieving universal health coverage. These initiatives, supported by the World Health Organization (WHO), are designed to enhance the efficiency of public healthcare expenditures and elevate the role of digital technologies in managing chronic diseases more effectively. The region is experiencing increasing Humira adoption in hospital settings.

The Japan market for Humira is expanding due to initiatives such as the “Healthy Aging” strategy, emphasizing chronic disease control in the elderly. Biologics are increasingly used in outpatient care, and local pharmaceutical firms are introducing biosimilar options tailored to the Japanese market. Digital health platforms are also enabling better treatment tracking.

The China Humira market is rapidly becoming a biosimilar powerhouse, with government policies encouraging fast-track approval and pricing regulation of biologics. Humira biosimilars are included in public insurance plans, while e-commerce health platforms and hospital-private partnerships enhance distribution.

Latin America Humira Market Trends

Latin America shows moderate but steady growth, with Brazil and Argentina leading. Biosimilar penetration is increasing due to economic constraints and updated public health procurement policies. Collaborations with global pharma companies are helping local firms scale production and improve quality standards.

The Brazil Humira market is expanding amid high autoimmune disorder incidence and support for biosimilar adoption. The government has prioritized chronic disease treatments under the SUS (Unified Health System), boosting availability in public hospitals. Local production and international licensing deals are further driving market accessibility.

Middle East & Africa Humira Market Trends

The Middle East and Africa are emerging markets for Humira, led by Saudi Arabia and the UAE. Government initiatives like Vision 2030 (Saudi Arabia) and healthcare digitalization (UAE) support biologics infrastructure. Local distributors are increasingly partnering with global biosimilar producers to ensure affordability and access.

The Saudi Arabia Humira market is expanding due to significant biopharma investments and rising rates of autoimmune and metabolic diseases. Health insurance reforms and government funding are facilitating biosimilar uptake. E-pharmacy platforms and telemedicine services are broadening access across urban and rural areas.

Key Humira Company Insights

The Humira market has entered a phase of rapid evolution following the drug’s loss of exclusivity in key global markets. In 2024, the competitive intensity has grown considerably, with a surge of biosimilars securing regulatory approvals and launching across various regions. This progression is significantly altering the competitive landscape by lowering treatment costs for healthcare systems and improving access for patients with autoimmune and inflammatory disorders.

New entrants in the biosimilar segment are employing advanced strategies, including high-concentration, citrate-free formulations and interchangeable approvals, to distinguish their offerings. Many companies are forming strategic alliances with multinational pharmaceutical firms to leverage established manufacturing infrastructure, global supply chains, and in-market expertise. These developments are contributing to a more diversified and accessible biologics market worldwide.

Recent Developments

• In April 2025, the U.S. Food and Drug Administration granted interchangeable status to YUFLYMA, a high-concentration, citrate-free biosimilar of Humira, developed by Celltrion, Inc. The designation applies across multiple inflammatory indications and allows pharmacists to substitute YUFLYMA for Humira without requiring a new prescription.

• In October 2024, Prime Therapeutics introduced new biosimilar strategies to expand access to cost-effective Humira alternatives. Starting in 2025, Prime will recommend biosimilars from four manufacturers: Organon (Hadlima), Teva (Simlandi), Sandoz (adalimumab-adaz), and Celltrion (adalimumab-aaty), offering flexible plan options including biosimilars-first or biosimilars-only models. These offerings include low-list-price biosimilars, with net monthly costs as low as USD 500-USD 600. They are supported through Prime’s conflict-free specialty pharmacy network, helping ensure broader access and affordability for millions of Americans.

• In December 2023, Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon, entered into a strategic distribution agreement with Sandoz. Under this agreement, Sandoz was granted exclusive rights to promote, sell, and distribute Adalimumab BS for subcutaneous injection (a biosimilar to Humira) in Japan.

Humira Market Report Scope

Global Humira Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Humira market report based on product, application, distribution channel, and region:

• Product Outlook (Revenue, USD Million; 2018 - 2030)

  • Branded

  • Biosimilar

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Rheumatoid Arthritis (RA)

  • Psoriatic Arthritis (PsA)

  • Crohn’s Disease (CD)

  • Ulcerative Colitis (UC)

  • Ankylosing Spondylitis

  • Others

• Distribution Channel Outlook (Revenue, USD Million; 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait